vimarsana.com
Home
Live Updates
Horizon Therapeutics plc: New Real-World Analysis of TEPEZZA
Horizon Therapeutics plc: New Real-World Analysis of TEPEZZA
Horizon Therapeutics plc: New Real-World Analysis of TEPEZZA (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
-- Analysis presented at American Thyroid Association Annual Meeting (ATA 2022) shows during a two-year period, 4.9% of patients who completed a full course of TEPEZZA were later prescribed a second
Related Keywords
Montreal ,
Quebec ,
Canada ,
United States ,
Jules Stein Eye Institute ,
California ,
Ireland ,
Los Angeles ,
American ,
Jeffreyw Sherman ,
Tina Ventura ,
Shoaib Ugradar ,
Ray Gordon ,
Rachel Vann ,
Instagram ,
Product Communications ,
Linkedin ,
American Thyroid Association Annual Meeting ,
Twitter ,
Conference Of American Thyroid Association ,
Visa ,
Drug Administration ,
Nasdaq ,
European Group On Grave Orbitopathy ,
Facebook ,
Annual Meeting ,
Thyroid Eye Disease ,
Clinical Activity Score ,
Eye Disease ,
Thyroid Eye ,
Inflammatory Bowel Disease ,
Full Prescribing Information ,
Ophthalmic Plastic ,
Additional Course ,
Teprotumumab Treatment ,
Annual Conference ,
American Thyroid Association ,
Longer Duration Inflammatory Thyroid Eye ,
Thyroid Associated ,
Grave Disease Is Mediated Through ,
Insulin Like Growth Factor ,
Grave Orbitopathy ,
Clinical Practice Guidelines ,
Medical Management ,
European Group ,
Vice President ,
Chief Investor Relations Officer ,
Horizon ,
Herapeutics ,
Meal ,
World ,
Analysis ,
Tepezza ,
Teprotumumab ,
Brbw ,
Vindicates ,
Mall ,
Percentage ,
People ,
Eceive ,
Second ,
Course ,
Treatment ,